(Medical Xpress)—Recent reports about arsenic in rice have sparked a great deal of panic among U.S. consumers. However, the average American who eats a variety of whole grains doesn't need to stress about arsenic, according ...
Nov 15, 2012
0
0
Imagine a world where you could never dine away from home, wear makeup, smell of sweet perfumes or eat a large percentage of food on store shelves. According to allergists at the American College of Allergy, Asthma and Immunology ...
Nov 8, 2012
0
0
(AP)—The U.S. Food and Drug Administration may consider new standards for the levels of arsenic in rice as consumer groups are calling for federal guidance on how much of the carcinogen can be present in food.
Sep 19, 2012
0
0
(HealthDay) -- Non-nutritive sweeteners like Splenda, Equal and Sweet'N Low may have a role to play in maintaining or even losing weight, as long as people don't use them as an excuse to treat themselves later with high-calorie ...
Jul 9, 2012
0
0
(AP) -- Advisers to government health regulators on Thursday recommended that that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over ...
May 10, 2012
0
0
US regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.
Apr 10, 2012
0
0
The US Food and Drug Administration on Tuesday warned consumers not to take a product called "Japan Rapid Weight Loss Diet Pills" because they contain a suspected cancer-causing agent.
Apr 3, 2012
0
0
(AP) -- The battle of the bulge has been a big, fat failure for U.S. drugmakers. But that hasn't stopped them from trying.
Feb 24, 2012
0
0
Persons with high cholesterol who received counseling regarding a diet that combined cholesterol-lowering foods such as soy protein, nuts and plant sterols over 6 months experienced a greater reduction in their low-density ...
Aug 23, 2011
0
1
In the primary result from the largest double-blind study ever completed to assess a drug's effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting ...
Aug 10, 2011
0
0
